2022

    1. Ventimiglia E, Bill-Axelson A, Bratt O, Montorsi F, Stattin P, Garmo H. Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden JAMA Network Open 2022 Sep. Sammanfattning
    2. Orrason AW, Styrke J, Garmo H, Stattin P. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int. 2022 Sep 11. Sammanfattning
    3. Godtman RA, Persson E, Bergengren O, Carlsson S, Johansson E, Robinsson D, Hugosson J, Stattin P. Surgeon volume and patient-reported urinary incontinence after radical prostatectomy. Population-based register study in Sweden. Scandcand J Urol 2022 sept. Sammanfattning
    4. Stattin P. How to survey adherence to guidelines by use of clinical cancer registers. Editorial comment to ’Swedish National Guidelines on prostate cancer part I and II’ by Bratt et al. Scand J Urol. 2022 Aug. Fulltext
    5. Gedeborg R, Loeb S, Styrke J, Kiiski-Berggren R, Garmo H, Stattin P. Susceptibility to SARS-Cov-2 infection and risk for severe COVID-19 in patients with prostate cancer on androgen deprivation therapy. Int J Cancer. 2022 Jul. Sammanfattning. Fulltext.
    6. Eugenio Ventimiglia, Anna Bill-Axelson, Jan Adolfsson, Markus Aly, Martin Eklund, Marcus Westerberg, Pär Stattin, Hans Garmo. Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data. European Urology Open Science 2022. Fulltext
    7. Lycken M, Bergengren O, Drevin L, Garmo H, Westerberg M, Axén E, Stranne J, Holmberg L, Bill-Axelson A. Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths. Eur Urol Open Sci. 2022 May. Sammanfattning. Fulltext
    8. Lin E, Garmo H, Van Hemelrijck M, Zethelius B, Stattin P, Hagström E, Adolfsson J, Crawley D. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes. JAMA Netw Open. 2022 Aug. Sammanfattning. Fulltext
    9. Jochems SHJ, Stattin P, Stocks T. Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus’s Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. Therapeutic Monitoring in Prostate Cancer Should Involve a Cotinine Test in Current Smokers: Smoking Cessation Remains a Cornerstone in Preventive Health Care Overall and for Men with Prostate Cancer.  Sammanfattning.
    10. Stenman C, Abrahamsson E, Redsäter M, Gnanapragasam VJ, Bratt O. Rates of Positive Abdominal Computed Tomography and Bone Scan Findings Among Men with Cambridge Prognostic Group 4 or 5 prostate cancer: A Nationwide Registry Study.  Eur Urol Open Sci. 2022 Jun. Sammanfattning
    11. Balabanova Y, Farahmand B, Garmo H, Stattin P, Brobert G. Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden. BMJ Open. 2022 May. Sammanfattning.
    12. Klein RJ, Vertosick E, Sjoberg D, Ulmert D, Rönn AC, Häggström C, Thysell E, Hallmans G, Dahlin A, Stattin P, Melander O, Vickers A, Lilja H. Prostate cancer polygenic risk score and prediction of lethal prostate cancer. NPJ Precis Oncol. 2022 Apr. Sammanfattning. Fulltext
    13. Jochems SHJ, Haggstrom C, Stattin P, Järvholm B, Stocks T. Association of blood pressure with prostate cancer risk by disease severity, and prostate cancer death: a pooled cohort study. Cancer Epidemiol Biomarkers Prev. 2022 May 5. Sammanfattning.
    14. Jochems SHJ, Fritz J, Häggström C, Järvholm B, Stattin P, Stocks T. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. 2022 May. Sammanfattning. Fulltext
    15. Braide K, Kindblom J, Thellenberg Karlsson C, Stattin P, Hugosson J, Månsson M. Risk of severe late toxicity after radiotherapy following radical prostatectomy – a nationwide study. BJU Int. 2022 May. Sammanfattning.
    16. Bonde TM, Westerberg M, Aly M, Eklund M, Adolfsson J, Bill-Axelson A, Garmo H, Stattin P, Robinson D. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scandinavian Journal of Urology 2022 May. Sammanfattning. Fulltext
    17. Van Hemelrijck M, Ventimiglia E, Robinson D, Gedeborg R, Holmberg L, Stattin P, Garmo H. Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Medical Informatics and Decision Making 2022 Feb. Sammanfattning. Fulltext
    18. Alverbratt C, Vikman H, Hjälm Eriksson M, Stattin P, Franck Lissbrant I. Time difference in retrieving clinical information in Patient-overview Prostate Cancer compared to electronic health records. Scand J Urol. 2022 Feb. Sammanfattning. Fulltext
    19. Balabanova Y, Farahmand B, Stattin P, Garmo H, Brobert G. Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden. BMC Urology. 2022 Feb. SammanfattningFulltext
    20. Gedeborg R, Garmo H, Thellenberg-Karlsson C, Fallara G, Styrke J, Franck Lissbrant I, Stattin P. Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study. Acta Oncol. 2022 Jan. Sammanfattning. Fulltext